CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production-Reference-Cited by-同舟云学术

CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production

Published:2001-03-20 Issue:7 Volume:98 Page:3964-3969
ISSN:0027-8424
Container-title:Proceedings of the National Academy of Sciences
language:en
Short-container-title:Proceedings of the National Academy of Sciences

Author:

Zeng G.,Wang X.,Robbins P. F.,Rosenberg S. A.,Wang R.-F.

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

Reference25 articles.

1. Human tumor antigens for cancer vaccine development

2. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

3. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes.

4. Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes

Cited by 164 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NY‐ESO‐1 antigen: A promising frontier in cancer immunotherapy;Clinical and Translational Medicine;2024-09

2. Characterization of genetic humanized mice with transgenic HLA DP401 or DRA but deficient in endogenous murine MHC class II genes upon Staphylococcus aureus pneumonia;Animal Models and Experimental Medicine;2023-05-29

3. Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms;Pharmaceutics;2022-07-11

4. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy;Journal for ImmunoTherapy of Cancer;2022-03

5. Cancer Vaccines: Promising Therapeutics or an Unattainable Dream;Vaccines;2021-06-18